Skip to content

A trial of the clinical efficacy and safety of combined Chinese herbal medicine granules with Promestriene for menopausal women with vulvovaginal atrophy

A trial of the clinical efficacy and safety of combined Chinese herbal medicine granules with Promestriene for menopausal women with vulvovaginal atrophy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009378
Enrollment
Unknown
Registered
2016-10-11
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvovaginal atrophy

Interventions

Experimental group:oral Chinese herbal medicine granules and topical Promestriene
The control group:Oral Chinese herbal medicine granules

Sponsors

Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 45-65 years old, menopause more than 1 year; 2. patients complained of vulvovaginal atrophy symptoms, such as vaginal dryness, vaginal or genital itching, painful sexual intercourse; 3. vaginal epithelial maturity index (VMI) = 10%, vaginal pH> 5; 4. FSH= 40mIU/ml, E2= 20 pg/ml; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With a history of reproductive system malignancy (such as endometrial cancer, ovarian cancer, cervical cancer, etc.) and breast cancer; 2. Unexplained uterine bleeding; 3. vulvovaginal other diseases, such as: vestibular prostatitis, vestibular glandular abscess, bacterial vaginitis, Candida albicans infection, trichomonas vaginitis; 4. Combined with severe cervicitis, cervical erosion, sexually transmitted diseases; 5. Liquid - based cytology abnormalities; 6. Endometrial thickness of vagina under ultrasound> 5mm; 7. B-breast hyperplasia or other significant abnormal breast hyperplasia; 8. Combined with severe disease of heart, liver, kidney, hematopoietic and other important organs and systems; 9. With diabetes, active central nervous system disorders or blood diseases; 10. Combined with neurological and mental disorders can not cooperate or unwilling to cooperate; 11. Those who are allergic to the constituents of the test drug and those who are allergic; 12. Take antidepressant, antipsychotic or containing its ingredients of drugs in 3 months; 13. Those who were treated within 1 month; 14. Patients who have participated in other clinical trials in the past 2 months; 15. Due to residence, work and other reasons can not be regularly followed up.

Design outcomes

Primary

MeasureTime frame
Vaginal health score;

Secondary

MeasureTime frame
Vaginitis score;Vaginal epithelial maturation index;Female Sexual Function Index;Improved Kupperman score;

Countries

China

Contacts

Public ContactDianrong Song

Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

Songdr58@126.com+86 13602115295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026